Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
Más filtros













Base de datos
Intervalo de año de publicación
1.
ACS Med Chem Lett ; 14(6): 788-793, 2023 Jun 08.
Artículo en Inglés | MEDLINE | ID: mdl-37312847

RESUMEN

A novel class of potent NaV1.7 inhibitors has been discovered. The replacement of diaryl ether in compound I was investigated to enhance mouse NaV1.7 inhibitory activity, which resulted in the discovery of N-aryl indoles. The introduction of the 3-methyl group is crucial for high NaV1.7 in vitro potency. The adjustment of lipophilicity led to the discovery of 2e. Compound 2e (DS43260857) demonstrated high in vitro potencies against both human and mouse NaV1.7 with high selectivity over NaV1.1, NaV1.5, and hERG. In vivo evaluations revealed 2e demonstrating potent efficacy in PSL mice with excellent pharmacokinetics.

2.
J Med Chem ; 63(18): 10204-10220, 2020 09 24.
Artículo en Inglés | MEDLINE | ID: mdl-32392056

RESUMEN

A highly potent, selective NaV1.7 inhibitor, DS-1971a, has been discovered. Exploration of the left-hand phenyl ring of sulfonamide derivatives (I and II) led to the discovery of novel series of cycloalkane derivatives with high NaV1.7 inhibitory potency in vitro. As the right-hand heteroaromatic ring affected the mechanism-based inhibition liability of CYP3A4, replacement of this moiety resulted in the generation of 4-pyrimidyl derivatives. Additionally, GSH adducts formation, which can cause idiosyncratic drug toxicity, was successfully avoided by this modification. An additional optimization led to the discovery of DS-1971a. In preclinical studies, DS-1971a demonstrated highly potent selective in vitro profile with robust efficacy in vivo. DS-1971a exhibited a favorable toxicological profile, which enabled multiple-dose studies of up to 600 mg bid or 400 mg tid (1200 mg/day) administered for 14 days to healthy human males. DS-1971a is expected to exert potent efficacy in patients with peripheral neuropathic pain, with a favorable safety profile.


Asunto(s)
Analgésicos/uso terapéutico , Hiperalgesia/tratamiento farmacológico , Canal de Sodio Activado por Voltaje NAV1.7/metabolismo , Pirazoles/uso terapéutico , Pirimidinas/uso terapéutico , Sulfonamidas/uso terapéutico , Bloqueadores del Canal de Sodio Activado por Voltaje/uso terapéutico , Analgésicos/síntesis química , Analgésicos/toxicidad , Animales , Descubrimiento de Drogas , Femenino , Humanos , Macaca fascicularis , Masculino , Ratones , Microsomas Hepáticos/metabolismo , Estructura Molecular , Pirazoles/síntesis química , Pirazoles/toxicidad , Pirimidinas/síntesis química , Pirimidinas/toxicidad , Relación Estructura-Actividad , Sulfonamidas/síntesis química , Sulfonamidas/toxicidad , Bloqueadores del Canal de Sodio Activado por Voltaje/síntesis química , Bloqueadores del Canal de Sodio Activado por Voltaje/toxicidad
3.
Biocontrol Sci ; 23(4): 241-244, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30584212

RESUMEN

Acanthamoeba castellanii, a ubiquitous organism in water environments, is pathogenic toward humans and also is a host for bacteria of the genus Legionella, a causative agent of legionellosis. Fragrance ingredients were investigated for their antibacterial activity against planktonic Legionella pneumophila, amoebicidal activity against A. castellanii, and inhibitory effect against L. pneumophila uptake into A. castellanii. Helional® exhibited relatively high antibacterial activity [minimum inhibitory concentration (MIC) , 32.0 µg/mL] . Anis aldehyde, canthoxal, helional® and vanillin exhibited amoebicidal activity (IC50 values, 58.4±2.0, 71.2±14.7, 66.8±8.3 and 49.1±2.5µg/mL, respectively) . L. pneumophila pretreatment with sub-MICs (0.25×MIC) of anis aldehyde, canthoxal, cortex aldehyde® 50 percent or vanillin evidently reduced L. pneumophila uptake into A. castellanii (p < 0.01) . Thus, fragrance ingredients were good candidates for disinfectant against L. pneumophila and A. castellanii.


Asunto(s)
Acanthamoeba castellanii/efectos de los fármacos , Antiinfecciosos/farmacología , Legionella pneumophila/efectos de los fármacos , Técnicas Microbiológicas/métodos , Odorantes/análisis , Acanthamoeba castellanii/microbiología , Pruebas de Sensibilidad Microbiana
4.
Plant Mol Biol ; 81(4-5): 461-75, 2013 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-23371559

RESUMEN

Rice seed has been used as a production platform for high value recombinant proteins. When mature human interleukin 7 (hIL-7) was expressed as a secretory protein in rice endosperm by ligating the N terminal glutelin signal peptide and the C terminal KDEL endoplasmic reticulum (ER) retention signal to the hIL-7 cytokine to improve production yield, this protein accumulated at levels visible by Coomassie Brilliant Blue staining. However, the production of this protein led not only to a severe reduction of endogenous seed storage proteins but also to a deterioration in grain quality. The appearance of aberrant grain phenotypes (such as floury and shrunken) was attributed to ER stress induced by the retention of highly aggregated unfolded hIL-7 in the ER lumen, and the expression levels of chaperones such as BiPs and PDIs were enhanced in parallel with the increase in hIL-7 levels. The activation of this ER stress response was shown to be mainly mediated by the OsIRE1-OsbZIP50 signal cascade, based on the appearance of unconventional splicing of OsbZIP50 mRNA and the induction of OsBiP4&5. Interestingly, the ER stress response could be induced by lower concentrations of hIL-7 versus other types of cytokines such as IL-1b, IL-4, IL-10, and IL-18. Furthermore, several ubiquitin 26S proteasome-related genes implicated in ER-associated degradation were upregulated by hIL-7 production. These results suggest that severe detrimental effects on grain properties were caused by proteo-toxicity induced by unfolded hIL-7 aggregates in the ER, resulting in the triggering of ER stress.


Asunto(s)
Estrés del Retículo Endoplásmico , Endospermo/citología , Endospermo/metabolismo , Interleucina-7/biosíntesis , Oryza/citología , Oryza/metabolismo , Animales , Estrés del Retículo Endoplásmico/genética , Degradación Asociada con el Retículo Endoplásmico/genética , Endospermo/genética , Endospermo/crecimiento & desarrollo , Regulación de la Expresión Génica de las Plantas , Glicosilación , Humanos , Espacio Intracelular/metabolismo , Ratones , Chaperonas Moleculares/metabolismo , Oryza/genética , Oryza/crecimiento & desarrollo , Fenotipo , Proteínas de Plantas/genética , Proteínas de Plantas/metabolismo , Plantas Modificadas Genéticamente , Estructura Cuaternaria de Proteína , Transporte de Proteínas , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa
5.
Biol Pharm Bull ; 33(6): 1067-9, 2010.
Artículo en Inglés | MEDLINE | ID: mdl-20522980

RESUMEN

CC chemokine receptor 4 (CCR4) is generally recognized as a preferential marker for T helper 2 cells, and we have previously reported morpholine-derivative CCR4 antagonists, RS-1154 and RS-1269. Here, we investigate the pharmacological profiles of a novel pyrimidine-derivative CCR4 antagonist, 2-{4-[2-(diethylamino)ethoxy]phenyl}-N-(2,4-difluorobenzyl)-5-fluoropyrimidin-4-amine (RS-1748), which showed potency to inhibit the bindings of [(125)I]CCL17 and [(35)S]GTPgammaS to human CCR4-expressing Chinese hamster ovary (CHO) cells with IC(50) values of 59.9 nM and 18.4 nM, respectively. Furthermore, RS-1748 inhibited ovalbumin-induced airway inflammation in guinea pigs at a dose of 10 mg/kg. These results indicate that RS-1748 would be a promising lead compound for developing a therapeutic agent against asthma.


Asunto(s)
Antiinflamatorios/uso terapéutico , Hiperreactividad Bronquial/tratamiento farmacológico , Inflamación/tratamiento farmacológico , Pirimidinas/uso terapéutico , Receptores CCR4/antagonistas & inhibidores , Animales , Antiinflamatorios/farmacología , Asma/tratamiento farmacológico , Hiperreactividad Bronquial/inducido químicamente , Hiperreactividad Bronquial/metabolismo , Células CHO , Quimiocina CCL17/metabolismo , Cricetinae , Cricetulus , Guanosina 5'-O-(3-Tiotrifosfato)/metabolismo , Cobayas , Humanos , Inflamación/inducido químicamente , Inflamación/metabolismo , Concentración 50 Inhibidora , Masculino , Ovalbúmina , Pirimidinas/farmacología
6.
Biosci Biotechnol Biochem ; 74(1): 182-4, 2010.
Artículo en Inglés | MEDLINE | ID: mdl-20057142

RESUMEN

Coenzyme Q10 (CoQ10) is a popular food supplement. Earlier, we successfully produced CoQ10 in rice, which normally produces predominately CoQ9. Here we developed efficient production of CoQ10 in rice by introducing the gene for decaprenyl diphosphate synthase into rice sugary and shrunken mutants. These rices produced 1.3 to 1.6 times as much CoQ10 as the earlier enriched rice did.


Asunto(s)
Ingeniería Genética/métodos , Mutación , Oryza/genética , Oryza/metabolismo , Ubiquinona/análogos & derivados , Transferasas Alquil y Aril/genética , Semillas/genética , Semillas/metabolismo , Ubiquinona/biosíntesis , Ubiquinona/metabolismo
7.
Eur J Pharmacol ; 596(1-3): 153-9, 2008 Oct 31.
Artículo en Inglés | MEDLINE | ID: mdl-18706408

RESUMEN

Neurokinins are known to induce neurogenic inflammation related to respiratory diseases. The effects of CS-003 ([1-{2-[(2R)-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl}spiro[benzo[c]thiophene-1(3H),4'-piperidine]-(2S)-oxide hydrochloride]), a novel triple neurokinin receptor antagonist, on several respiratory disease models were evaluated in guinea pigs. As we have already shown that CS-003 is intravenously effective, we first determined if CS-003 was orally effective. CS-003 dose-dependently inhibited substance P-induced tracheal vascular hyperpermeability, neurokinin A- and neurokinin B-induced bronchoconstriction with ID(50) values of 3.6, 1.3 and 0.89 mg/kg (p.o.), respectively. CS-003 (10 mg/kg, p.o.) inhibited the number of coughs induced by capsaicin aerosol (P<0.01) and the antitussive effect was comparable to that of codeine. CS-003 (10 mg/kg, p.o.) also inhibited airway hyperresponsiveness to methacholine chloride in ovalbumin-induced asthma models (P<0.01), a milder one and a severer one. On the other hand, montelukast (10 mg/kg, p.o.), a leukotriene receptor antagonist, significantly inhibited the hyperresponsiveness only in the milder model (P<0.05). In an ovalbumin-induced rhinitis model, oral administration of CS-003 inhibited nasal blockade in a dose-dependent manner and the inhibitory effect was comparable to that of dexamethasone (10 mg/kg, p.o.). CS-003 (i.v.) also dose-dependently inhibited cigarette smoke-induced bronchoconstriction, tracheal vascular hyperpermeability and mucus secretion. These data show that CS-003, a potent orally active triple neurokinin receptor antagonist, may be useful for the treatment of respiratory diseases associated with neurokinins, such as allergic asthma, allergic rhinitis, chronic obstructive pulmonary disease and cough.


Asunto(s)
Óxidos S-Cíclicos/farmacología , Morfolinas/farmacología , Receptores de Taquicininas/antagonistas & inhibidores , Enfermedades Respiratorias/tratamiento farmacológico , Administración Oral , Animales , Asma/tratamiento farmacológico , Asma/inmunología , Broncoconstricción/efectos de los fármacos , Permeabilidad Capilar/efectos de los fármacos , Capsaicina , Tos/inducido químicamente , Tos/tratamiento farmacológico , Óxidos S-Cíclicos/administración & dosificación , Óxidos S-Cíclicos/uso terapéutico , Modelos Animales de Enfermedad , Cobayas , Masculino , Morfolinas/administración & dosificación , Morfolinas/uso terapéutico , Moco/metabolismo , Ovalbúmina , Enfermedad Pulmonar Obstructiva Crónica/tratamiento farmacológico , Rinitis/tratamiento farmacológico , Rinitis/inmunología , Humo , Nicotiana , Tráquea/irrigación sanguínea , Tráquea/metabolismo
8.
Eur J Pharmacol ; 586(1-3): 306-12, 2008 May 31.
Artículo en Inglés | MEDLINE | ID: mdl-18353309

RESUMEN

Neurokinins are known to induce neurogenic inflammation related to respiratory diseases, though there is little information on triple neurokinin receptor antagonists. The pharmacological properties of the novel triple neurokinin 1, 2 and 3 receptor antagonist [1-(2-[(2R)-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl)spiro[benzo[c]thiophene-1(3H),4'-piperidine]-(2S)-oxide hydrochloride] (CS-003) were evaluated in this study. The binding affinities of CS-003 were evaluated with human and guinea pig neurokinin receptors. As well, the in vivo antagonism of CS-003 against exogenous neurokinins and effects on capsaicin-induced and citric acid-induced responses were investigated in guinea pigs. CS-003 exhibited high affinities for human neurokinin 1, neurokinin 2 and neurokinin 3 receptors with Ki values (mean+/-S.E.M.) of 2.3+/-0.52, 0.54+/-0.11 and 0.74+/-0.17 nM, respectively, and for the guinea pig receptors with Ki values of 5.2+/-1.4, 0.47+/-0.075 and 0.71+/-0.27 nM, respectively. Competitive antagonism was indicated in a Schild analysis of substance P-, neurokinin A- and neurokinin B-induced inositol phosphate formation with pA2 values of 8.7, 9.4 and 9.5, respectively. CS-003 inhibited substance P-induced tracheal vascular hyperpermeability, neurokinin A- and neurokinin B-induced bronchoconstriction with ID50 values of 0.13, 0.040 and 0.063 mg/kg (i.v.), respectively. CS-003 also inhibited capsaicin-induced bronchoconstriction (ID50: 0.27 mg/kg, i.v.), which is caused by endogenous neurokinins. CS-003 significantly inhibited citric acid-induced coughs and the effect was greater than those of other selective neurokinin receptor antagonists. CS-003 is a potent antagonist of triple neurokinin receptors and may achieve the best therapeutic efficacy on respiratory diseases associated with neurokinins compared to selective neurokinin receptor antagonists.


Asunto(s)
Óxidos S-Cíclicos/farmacología , Morfolinas/farmacología , Neuroquinina A/antagonistas & inhibidores , Neuroquinina A/farmacología , Neuroquinina B/antagonistas & inhibidores , Neuroquinina B/farmacología , Antagonistas del Receptor de Neuroquinina-1 , Receptores de Neuroquinina-2/antagonistas & inhibidores , Receptores de Neuroquinina-3/antagonistas & inhibidores , Animales , Bronquios/efectos de los fármacos , Células COS , Permeabilidad Capilar/efectos de los fármacos , Capsaicina/antagonistas & inhibidores , Capsaicina/farmacología , Chlorocebus aethiops , Ácido Cítrico , Tos/inducido químicamente , Tos/prevención & control , Dipéptidos/farmacología , Relación Dosis-Respuesta a Droga , Cobayas , Humanos , Técnicas In Vitro , Indoles/farmacología , Fosfatos de Inositol/biosíntesis , Masculino , Datos de Secuencia Molecular , Receptores de Neuroquinina-1/metabolismo , Receptores de Neuroquinina-2/metabolismo , Receptores de Neuroquinina-3/metabolismo , Sustancia P/farmacología , Tráquea/irrigación sanguínea , Tráquea/efectos de los fármacos
9.
FEBS Lett ; 580(3): 955-9, 2006 Feb 06.
Artículo en Inglés | MEDLINE | ID: mdl-16442107

RESUMEN

Coenzyme Q (CoQ), an electron transfer molecule in the respiratory chain and a lipid-soluble antioxidant, is present in almost all organisms. Most cereal crops produce CoQ9, which has nine isoprene units. CoQ10, with 10 isoprene units, is a very popular food supplement. Here, we report the genetic engineering of rice to produce CoQ10 using the gene for decaprenyl diphosphate synthase (DdsA). The production of CoQ9 was almost completely replaced with that of CoQ10, despite the presence of endogenous CoQ9 synthesis. DdsA designed to express at the mitochondria increased accumulation of total CoQ amount in seeds.


Asunto(s)
Transferasas Alquil y Aril/genética , Antioxidantes/fisiología , Mitocondrias/genética , Oryza/genética , Semillas/genética , Ubiquinona/análogos & derivados , Transferasas Alquil y Aril/metabolismo , Secuencia de Bases , Coenzimas , Productos Agrícolas/enzimología , Productos Agrícolas/genética , Transporte de Electrón/fisiología , Ingeniería Genética/métodos , Mitocondrias/enzimología , Datos de Secuencia Molecular , Oryza/enzimología , Plantas Modificadas Genéticamente , Semillas/enzimología , Terpenos/metabolismo , Ubiquinona/biosíntesis , Ubiquinona/genética
10.
Eur J Pharmacol ; 498(1-3): 287-94, 2004 Sep 13.
Artículo en Inglés | MEDLINE | ID: mdl-15364007

RESUMEN

In this study, we investigated the involvement of neurokinin NK3 receptors in a severe asthma model prepared by administering ovalbumin via inhalation three times to systemically sensitized guinea pigs. [3H]senktide, a neurokinin NK3 receptor ligand, showed significant specific binding to the lungs from the model animals, but not to those from negative control animals. The airway responsiveness to intravenous neurokinin B, a neurokinin NK3 receptor agonist, was increased in the model, indicating an increase in functional NK3 receptors. Furthermore, SB 223956 ((-)-3-methoxy-2-phenyl-N-[(1S)-phenylpropyl]quinoline-4-carboxamide), a selective neurokinin NK3 receptor antagonist, significantly inhibited the ovalbumin-induced airway hyperresponsiveness to inhaled methacholine, but it did not show significant effects on the ovalbumin-induced airway narrowing and eosinophil accumulation. These results suggest that the expressed neurokinin NK3 receptors in the severe asthma model are involved in the development of airway hyperresponsiveness.


Asunto(s)
Asma/metabolismo , Receptores de Neuroquinina-3/metabolismo , Sustancia P/análogos & derivados , Animales , Asma/inmunología , Benzamidas/metabolismo , Unión Competitiva , Líquido del Lavado Bronquioalveolar/citología , Broncoconstricción/efectos de los fármacos , Broncoconstrictores/farmacología , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Eosinófilos/efectos de los fármacos , Eosinófilos/patología , Cobayas , Pulmón/efectos de los fármacos , Pulmón/patología , Pulmón/fisiopatología , Masculino , Cloruro de Metacolina/farmacología , Neuroquinina B/farmacología , Ovalbúmina/inmunología , Fragmentos de Péptidos/metabolismo , Piperidinas/metabolismo , Receptores de Neuroquinina-3/antagonistas & inhibidores , Sustancia P/metabolismo , Tritio
11.
DNA Res ; 11(2): 93-9, 2004 Apr 30.
Artículo en Inglés | MEDLINE | ID: mdl-15449542

RESUMEN

The complete nucleotide sequence of the chloroplast genome of sugarcane (Saccharum officinarum) has been determined. It is a circular double-stranded DNA molecule, 141,182 bp in size, and is composed of a large single copy of 83,048 bp, a small single copy of 12,544 bp, and a pair of inverted repeat regions of 22,795 bp each. A comparative analysis among monocots showed that the sugarcane chloroplast genome was very similar to maize but not to rice or wheat. Between sugarcane and maize at the rps16-trnQ (UUG) region, however, a length polymorphism was identified. With regard to insertions/deletions equal to or longer than 5 bp, a total of 53 insertion and 31 deletion events were identified in the sugarcane chloroplast genome. Of the 84 loci identified, a pair of direct repeat sequences was located side by side in a tandem fashion in 47 loci (56.0%). A recombination event during plant evolution is discussed at two sites between the sugarcane and tobacco chloroplast genomes.


Asunto(s)
Mapeo Cromosómico , ADN de Cloroplastos/genética , Genoma de Planta , Saccharum/genética , Secuencia de Bases , Cartilla de ADN , Variación Genética , Datos de Secuencia Molecular , Mutación/genética , Alineación de Secuencia , Análisis de Secuencia de ADN
12.
Int Arch Allergy Immunol ; 134(4): 263-72, 2004 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-15205557

RESUMEN

BACKGROUND: Involvement of neurokinins in asthma has been previously pointed out by several reports. However, the relationship between neurokinins and the severity of asthma has remained unclear. We developed a model of mild asthma (model I) and severe asthma (model II) in guinea pigs, and investigated the function of neurokinins in both models. METHODS: In models I and II, systemically sensitized guinea pigs were made to inhale ovalbumin once and three times, respectively. Substance P (SP) and neurokinin A (NKA) concentrations in the bronchoalveolar lavage fluid (BALF) were measured in models I and II. Then, the effects of a capsaicin pretreatment, which depletes neurokinins, in both animal models on airway narrowing induced by the last ovalbumin inhalation, airway hyperresponsiveness to inhaled methacholine, and eosinophil accumulation in BALF, were investigated. RESULTS: SP concentration tended to increase and the NKA concentration increased significantly in model II, but not in model I. Capsaicin pretreatment significantly inhibited the late bronchial response that was observed 2-6 h after the last ovalbumin inhalation, airway hyperresponsiveness and eosinophil accumulation in model II. On the other hand, it had no effects on the responses in model I. CONCLUSION: It is suggested that the more severe the disease, the greater the involvement of neurokinins.


Asunto(s)
Asma/metabolismo , Neuroquinina A/metabolismo , Sustancia P/metabolismo , Administración por Inhalación , Resistencia de las Vías Respiratorias/efectos de los fármacos , Alérgenos/efectos adversos , Animales , Biomarcadores/análisis , Pruebas de Provocación Bronquial , Líquido del Lavado Bronquioalveolar/química , Broncoconstrictores/efectos adversos , Capsaicina/farmacología , Modelos Animales de Enfermedad , Eosinófilos/efectos de los fármacos , Eosinófilos/metabolismo , Cobayas , Pulmón/metabolismo , Masculino , Cloruro de Metacolina/efectos adversos , Neprilisina/efectos de los fármacos , Neprilisina/metabolismo , Neuroquinina A/efectos de los fármacos , Hipersensibilidad Respiratoria/tratamiento farmacológico , Hipersensibilidad Respiratoria/etiología , Índice de Severidad de la Enfermedad , Sustancia P/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA